T. Rowe Price Associates’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $293K | Buy |
66,223
+5,881
| +10% | +$31.8K | ﹤0.01% | 2691 |
|
|
2025
Q4 | $384K | Buy |
60,342
+3,215
| +6% | +$22.4K | ﹤0.01% | 2515 |
|
|
2025
Q3 | $533K | Buy |
57,127
+2,382
| +4% | +$24.1K | ﹤0.01% | 2332 |
|
|
2025
Q2 | $789K | Buy |
54,745
+3,536
| +7% | +$34.9K | ﹤0.01% | 2089 |
|
|
2025
Q1 | $354K | Sell |
51,209
-6,095
| -11% | -$38.3K | ﹤0.01% | 2395 |
|
|
2024
Q4 | $304K | Buy |
57,304
+2,196
| +4% | +$12K | ﹤0.01% | 2505 |
|
|
2024
Q3 | $202K | Hold |
55,108
| – | – | ﹤0.01% | 2649 |
|
|
2024
Q2 | $151K | Buy |
55,108
+15,808
| +40% | +$52.9K | ﹤0.01% | 2666 |
|
|
2024
Q1 | $137K | Hold |
39,300
| – | – | ﹤0.01% | 2718 |
|
|
2023
Q4 | $57K | Hold |
39,300
| – | – | ﹤0.01% | 2792 |
|
|
2023
Q3 | $58K | Hold |
39,300
| – | – | ﹤0.01% | 2762 |
|
|
2023
Q2 | $62K | Hold |
39,300
| – | – | ﹤0.01% | 2776 |
|
|
2023
Q1 | $61K | Hold |
39,300
| – | – | ﹤0.01% | 2764 |
|
|
2022
Q4 | $66K | Buy |
39,300
+16,800
| +75% | +$26.6K | ﹤0.01% | 2778 |
|
|
2022
Q3 | $28K | Hold |
22,500
| – | – | ﹤0.01% | 2894 |
|
|
2022
Q2 | $38K | Sell |
22,500
-30,772
| -58% | -$60.2K | ﹤0.01% | 2890 |
|
|
2022
Q1 | $131K | Buy |
53,272
+17,600
| +49% | +$48.1K | ﹤0.01% | 2801 |
|
|
2021
Q4 | $133K | Sell |
35,672
-1,000
| -3% | -$5.4K | ﹤0.01% | 2829 |
|
|
2021
Q3 | $230K | Buy |
36,672
+11,281
| +44% | +$93K | ﹤0.01% | 2674 |
|
|
2021
Q2 | $250K | Buy |
25,391
+7,113
| +39% | +$62K | ﹤0.01% | 2645 |
|
|
2021
Q1 | $171K | Sell |
18,278
-9,916
| -35% | -$78.6K | ﹤0.01% | 2723 |
|
|
2020
Q4 | $135K | Buy |
28,194
+11,500
| +69% | +$56.1K | ﹤0.01% | 2603 |
|
|
2020
Q3 | $67K | Buy |
+16,694
| New | +$80.5K | ﹤0.01% | 2536 |
|
Other funds holding NAGE
SW
VCM
TCM
